Consecutive Affinity and Ion-Exchange Chromatography for AAV9 Vectors Purification

<b>Background:</b> Irrespective of the rapid development of AAV-based gene therapy, the production of clinical-grade vectors has a bottleneck resulting from product-related impurities such as empty and partially filled capsids, which lack a functional recombinant genome. <b>Methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Ozgun Firat Duzenli, George Aslanidi
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/13/2/361
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850081044158480384
author Ozgun Firat Duzenli
George Aslanidi
author_facet Ozgun Firat Duzenli
George Aslanidi
author_sort Ozgun Firat Duzenli
collection DOAJ
description <b>Background:</b> Irrespective of the rapid development of AAV-based gene therapy, the production of clinical-grade vectors has a bottleneck resulting from product-related impurities such as empty and partially filled capsids, which lack a functional recombinant genome. <b>Methods:</b> In the current study, we applied the sequential affinity chromatography (AC)- and anion-exchange chromatography (AEX)-based method for purification of AAV9 vector harboring single-stranded genome encoding the fusion of firefly luciferase (fLuc)-yellow fluorescent protein (YFP) under chicken beta actin (CBA) promoter. We assessed the efficiency of two different pre-packed cross-linked sepharose and one monolithic AEX columns following AC purification to separate fully encapsulated with recombinant DNA AAV vectors from byproducts. <b>Results:</b> We showed the possibility to achieve approximately 20–80% recovery and over 90% calculated DNA-containing/empty capsid ratio depending on column and buffers composition. Additionally, we confirmed the infectivity of AAV by in vitro luciferase assay regardless of recovery method from different AEX columns. <b>Conclusions:</b> Our purification data indicate the effectiveness of dual chromatography method to obtain rAAV9 vectors with DNA-containing capsid content over 90%.
format Article
id doaj-art-926afd1535dd48f4b4ac7b2ea88e1ee8
institution DOAJ
issn 2227-9059
language English
publishDate 2025-02-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj-art-926afd1535dd48f4b4ac7b2ea88e1ee82025-08-20T02:44:49ZengMDPI AGBiomedicines2227-90592025-02-0113236110.3390/biomedicines13020361Consecutive Affinity and Ion-Exchange Chromatography for AAV9 Vectors PurificationOzgun Firat Duzenli0George Aslanidi1The Hormel Institute, University of Minnesota, 801 16th Avenue NE, Austin, MN 55912, USAThe Hormel Institute, University of Minnesota, 801 16th Avenue NE, Austin, MN 55912, USA<b>Background:</b> Irrespective of the rapid development of AAV-based gene therapy, the production of clinical-grade vectors has a bottleneck resulting from product-related impurities such as empty and partially filled capsids, which lack a functional recombinant genome. <b>Methods:</b> In the current study, we applied the sequential affinity chromatography (AC)- and anion-exchange chromatography (AEX)-based method for purification of AAV9 vector harboring single-stranded genome encoding the fusion of firefly luciferase (fLuc)-yellow fluorescent protein (YFP) under chicken beta actin (CBA) promoter. We assessed the efficiency of two different pre-packed cross-linked sepharose and one monolithic AEX columns following AC purification to separate fully encapsulated with recombinant DNA AAV vectors from byproducts. <b>Results:</b> We showed the possibility to achieve approximately 20–80% recovery and over 90% calculated DNA-containing/empty capsid ratio depending on column and buffers composition. Additionally, we confirmed the infectivity of AAV by in vitro luciferase assay regardless of recovery method from different AEX columns. <b>Conclusions:</b> Our purification data indicate the effectiveness of dual chromatography method to obtain rAAV9 vectors with DNA-containing capsid content over 90%.https://www.mdpi.com/2227-9059/13/2/361adeno-associated vectorschromatographydownstream purificationAEX
spellingShingle Ozgun Firat Duzenli
George Aslanidi
Consecutive Affinity and Ion-Exchange Chromatography for AAV9 Vectors Purification
Biomedicines
adeno-associated vectors
chromatography
downstream purification
AEX
title Consecutive Affinity and Ion-Exchange Chromatography for AAV9 Vectors Purification
title_full Consecutive Affinity and Ion-Exchange Chromatography for AAV9 Vectors Purification
title_fullStr Consecutive Affinity and Ion-Exchange Chromatography for AAV9 Vectors Purification
title_full_unstemmed Consecutive Affinity and Ion-Exchange Chromatography for AAV9 Vectors Purification
title_short Consecutive Affinity and Ion-Exchange Chromatography for AAV9 Vectors Purification
title_sort consecutive affinity and ion exchange chromatography for aav9 vectors purification
topic adeno-associated vectors
chromatography
downstream purification
AEX
url https://www.mdpi.com/2227-9059/13/2/361
work_keys_str_mv AT ozgunfiratduzenli consecutiveaffinityandionexchangechromatographyforaav9vectorspurification
AT georgeaslanidi consecutiveaffinityandionexchangechromatographyforaav9vectorspurification